Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (9458)	3/30/1999 9:47:00 PM
From: Bluegreen	Read Replies (2) \| Respond to of 17367

>>>>>>''Drug safety is a critical issue that concerns everyone--patients, health care providers, hospitals, managed care organizations, and pharmaceutical firms,'' said Kenneth I. Kaitin, Director of the Tufts Center. ''While a number of high profile drugs have recently been withdrawn from the market, the real question is whether the rate of withdrawals has increased given the fact that more drugs are being marketed than ever before.''<<<<<<<< What??? What kind of lame excuse is THAT? There you have it in a nutshell, Robert S. Typical of the FDA. Ramp up programs to speed up approval but don't implement any changes to beef up safety monitoring to compensate. Like putting a jet engine on a old biplane. Great just great. Next they will probably use the lack of manpower excuse instead of streamlining and figuring low cost solutions for safety monitoring.